证券代码：688469 证券简称：芯联集成 公告编号：2025-062 芯联集成电路制造股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 芯联集成电路制造股份有限公司第二届监事会第九次会议于2025年12月5日以现场结合通讯的方式召 开。会议通知于2025年11月28日向全体监事发出。会议应出席监事5人，实际出席监事5人，会议由监事 会主席王永先生主持。会议的召集和召开符合《中华人民共和国公司法》（以下简称"《公司法》"）等 法律法规和《公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于取消监事会、变更注册资本、修订公司章程并授权办理工商变更登记的议案》 监事会认为：根据《公司法》《关于新〈公司法〉配套制度规则实施相关过渡期安排》《上市公司章程 指引》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号 一一规范运作》等法律法规、规范性文件的最新规定，为进一步规范公司运作机制，结合公司实际情 况，同意公司取 ...

中国外运（601598）(00598)发布公告，2025年12月5日，公司召开第四届董事会第十九次会议，审议通 过了《关于公司股票期权激励计划(第一期)第三个行权期行权条件未成就的议案》以及《关于拟注销部 分股票期权的议案》，《公司股票期权激励计划(第一期)》第三个行权期行权条件未成就，所授予的 2151.31万份股票期权未生效，并将由公司注销;同时，公司拟对第二个行权期已授予但未行权的50.42万 份股票期权予以注销。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002706 证券简称：良信股份 公告编号： 2025-072 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大遗 漏。 上海良信电器股份有限公司第七届董事会第七次会议于2025年12月3日在公司一号会议室召开，本次会 议通知和议案已于2025年11月28日以电话、电子邮件等形式发出。应参加本次会议表决的董事为9人， 实际参加本次会议表决的董事为9人，公司高级管理人员列席了会议。董事长任思龙先生主持会议，会 议符合《公司法》和《公司章程》的有关规定，会议合法有效。 表决结果：同意9票，反对0票，弃权0票 会议审议并通过了以下议案： 一、审议通过了《关于变更回购股份用途的议案》 《关于变更回购股份用途的公告》详见2025年12月4日巨潮资讯网（www.cninfo.com.cn）。 表决结果：同意9票，反对0票，弃权0票 二、审议通过了《关于＜2025年奋斗者3号股票期权激励计划（草案）＞及其摘要的议案》 经审议，董事会认为：公司制订的《2025年奋斗者3号股票期权激励计划（草案）》可以进一步健全公 司长效激励约束 ...

Core Points - The company announced an adjustment to the conversion price of its convertible bonds, "Zhengfan Convertible Bonds," from 38.52 CNY per share to 38.45 CNY per share, effective from December 5, 2025 [5][6][8] - The adjustment is in accordance with the relevant provisions outlined in the prospectus for the convertible bonds [3][4] - The adjustment was necessitated by the company's stock option incentive plan, which saw a total of 1,207,000 shares converted during the period [2][10] Summary by Sections Conversion Price Adjustment - The conversion price before adjustment was 38.52 CNY per share, and after adjustment, it is set to be 38.45 CNY per share [5][6] - The adjustment formula used for the conversion price is based on the issuance of new shares and stock dividends [4][6] Stock Option Incentive Plan - The company’s second phase of the stock option incentive plan allows for a total of 3,134,800 shares to be exercised between December 17, 2024, and December 2, 2025 [10][21] - The total number of shares converted during this period was 1,207,000 shares, resulting in an increase in total share capital from 292,923,454 shares to 294,131,009 shares [2][21] Financial Impact - The funds raised from the exercise of stock options amounted to approximately 67.24 million CNY, which will be used to supplement the company's working capital [21] - The results of the stock option exercise are not expected to have a significant impact on the company's financial status or operating results [21]

证券代码：600196 证券简称：复星医药 公告编号：临2025-190 上海复星医药（集团）股份有限公司关于 2025年A股股票期权激励计划首次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性、完整性承担法律责任。 重要内容提示： ●A股期权首次授予登记日：2025年12月2日 ●A股期权首次授予登记数量：4,446,400份 根据《上海复星医药（集团）股份有限公司2025年A股股票期权激励计划》（以下简称"2025年A股期权 计划"或"本次激励计划"）及上海复星医药（集团）股份有限公司（以下简称"本公司"）2025年第一次 临时股东会的授权，本次激励计划首次授予及登记工作已完成，现将相关事项公告如下： 一、本次激励计划首次授予情况 2025年11月4日，本公司第十届董事会第十四次会议审议通过关于2025年A股期权计划首次授予相关事 项的议案，董事会认为本次激励计划首次授予的条件已经成就，同意以2025年11月4日作为首次授予 日、向共计195名首次授予激励对象授予合计4,535,100份A股期权，并办理该授予所需的相关事宜。该 议案 ...

Core Points - The company has announced the second exercise period for its stock option incentive plan, which will take place from December 8, 2025, to December 20, 2025 [1] - The board of directors approved the achievement of exercise conditions for the second exercise period of the stock option incentive plan during a meeting held on January 14, 2025 [1][2] - The total number of stock options available for exercise in the second period is 242,665 shares, which represents one-third of the total options granted to 13 incentive recipients [11][14] Summary of Stock Option Incentive Plan Approval and Implementation - The stock option incentive plan was approved through various meetings held by the board and supervisory committee in late 2020, with independent opinions provided by the independent directors [2][3] - The plan included a public announcement of the intended recipients and received approval from the indirect controlling shareholder [2][3] Historical Granting and Exercise - The first exercise period for the stock options was from January 21, 2023, to January 20, 2024, with a total of 3,334,792 options available for exercise, but no options were exercised by the end of this period [9] - The second exercise period for the stock options is set from May 31, 2024, to January 20, 2025, with 3,196,126 options available for exercise [10] Conditions for Exercise - The conditions for the second exercise period have been met, allowing the 13 incentive recipients to exercise their options [11][14] - The company has outlined procedures for handling options that do not meet exercise conditions due to employment changes [11] Financial and Legal Considerations - The company has accounted for the stock option expenses according to relevant accounting standards, ensuring that the exercise of options will not significantly impact its financial status [15] - Legal opinions confirm that the exercise conditions have been satisfied in accordance with applicable regulations [16]

Group 1 - The company has approved the use of idle raised funds for cash management, with a maximum daily balance of RMB 500 million for a period of 12 months [1][2] - The company has signed an agreement with China Construction Bank to invest RMB 400 million in structured deposits, which are linked to the performance of financial derivatives [2][3] - The cash management products purchased are principal-protected and meet high safety and liquidity standards, ensuring no change in the intended use of raised funds [3][4] Group 2 - The cash management initiative is expected to enhance the efficiency of fund utilization and generate investment returns for the company and its shareholders [4] - The company has completed the registration of its 2025 stock option incentive plan, granting a total of 19.95 million stock options to 259 individuals [5][6] - The stock options have a maximum validity of 36 months and can be exercised after a 12-month waiting period, with specific conditions outlined for exercising the options [9][10]

Core Viewpoint - The company has completed the cancellation of stock options from the 2022 stock option incentive plan due to unmet performance targets for the third exercise period [1][4]. Group 1: Stock Option Cancellation - The board of directors approved the cancellation of stock options for 27 incentive participants, totaling 1 million stock options, due to failure to meet performance conditions [3]. - The performance assessment criteria required the company to meet both "main business income" and "net profit" targets for the stock options to be exercisable [2][3]. - The cancellation process was completed on November 25, 2025, and does not affect the company's capital structure or financial results significantly [4]. Group 2: Performance Assessment Criteria - The performance targets for the stock options were based on audited consolidated financial statements, specifically excluding non-recurring gains and losses [2]. - If the company met both performance targets, 100% of the stock options would be eligible for exercise; if only one target was met, 50% would be eligible; if neither was met, none would be exercisable [2]. - The cancellation aligns with the regulations set forth in the "Management Measures for Equity Incentives of Listed Companies" and the specific incentive plan [4].

Core Viewpoint - The company has completed the registration of its stock option incentive plan for 2025, which includes the granting of 5 million stock options to 12 individuals, aimed at enhancing employee motivation and aligning their interests with those of shareholders [2][5][16]. Group 1: Incentive Plan Overview - The stock option incentive plan was approved by the company's board and supervisory committee through a series of meetings held in April and May 2025 [2][3][4]. - The stock options will be granted on October 23, 2025, with a total of 5 million options reserved for 12 individuals [5][6]. - The effective period of the incentive plan is up to 54 months from the date of the first grant registration [6]. Group 2: Granting and Exercise Conditions - The waiting periods for the stock options are set at 12, 24, and 36 months [7]. - The exercise of stock options is subject to specific conditions, including the company's financial performance and the absence of certain disqualifying events [10][11]. - The exercise price for the stock options is set at 3.87 yuan per share [10]. Group 3: Performance Assessment - The performance assessment for the stock options will be conducted annually over three accounting years (2025-2027), focusing on revenue and net profit targets [12][13]. - Individual performance assessments will also be conducted, with results categorized into seven levels, affecting the number of options that can be exercised [13]. Group 4: Registration and Financial Impact - The stock options have been registered with the China Securities Depository and Clearing Corporation, with the registration completion date set for November 20, 2025 [14][15]. - The implementation of the incentive plan is expected to have an impact on the company's financial performance, with estimated costs calculated using the Black-Scholes model [16].

Core Viewpoint - The announcement details the completion of the stock option incentive plan for Hunan Keli Yuan New Energy Co., Ltd., including the number of options granted and the decision-making process involved in the plan [2][14]. Group 1: Stock Option Plan Details - The stock option reserve grant registration was completed on November 20, 2025 [2]. - A total of 5 million stock options were reserved for 12 individuals [2][9]. - The stock option grant date is set for October 23, 2025, with an exercise price of 3.87 yuan per share [9]. Group 2: Decision-Making Process - The board of directors approved the stock option incentive plan on April 21, 2025, after discussions in various meetings [3][4]. - The plan underwent a public disclosure period from April 22 to May 1, 2025, during which no objections were raised [3]. - The annual shareholders' meeting on May 20, 2025, also approved the plan [4]. Group 3: Terms and Conditions - The effective period of the stock options is up to 54 months from the completion of the initial grant registration [6]. - The waiting periods for the stock options are set at 12, 24, and 36 months [6]. - The exercise of options is subject to specific conditions, including company performance metrics and individual performance assessments [11][12]. Group 4: Financial Impact - The company will use the Black-Scholes model to calculate the fair value of the stock options, which will impact the company's financial performance [15]. - The estimated incentive costs from the stock option plan are expected to influence the company's operating results, while also potentially enhancing employee motivation and company value [16].